期刊文献+

6-姜酚对脑缺血损伤模型小鼠的保护作用 被引量:5

下载PDF
导出
摘要 目的探讨6-姜酚对脑缺血模型小鼠的保护作用。方法 50只雄性昆明种小鼠随机分为5组:假手术组;DMSO对照组;6-姜酚低剂量(0.1μg)组;6-姜酚中剂量(1μg)组;6-姜酚高剂量(3μg)组。采用线栓法制作脑缺血模型,检测各组的脑梗死体积。结果 6-姜酚低剂量和中剂量组脑梗死体积无明显减小,6-姜酚高剂量组脑梗死体积缩小较为明显(P<0.01)。结论 3μg 6-姜酚脑室内注射能够减小脑梗死体积,保护脑缺血模型小鼠。
机构地区 中山大学药学院
出处 《山东医药》 CAS 北大核心 2011年第52期41-43,I0002,共4页 Shandong Medical Journal
基金 国家自然科学基金资助项目(30970935)
  • 相关文献

参考文献7

  • 1Koo KL, Ammit M, Tran VH, et al. Gingerols and related ana- logues inhibit arachidonic acid-induced human plateletserotonin re- lease and aggregation [ J ]. Thromb Res, 2001,103 (5) :387-397.
  • 2姜泉,夏斌.6-姜酚对大鼠脑缺血再灌注炎性细胞因子的影响[J].咸宁学院学报(医学版),2007,21(4):281-283. 被引量:4
  • 3Zick SM, Djuric Z, Ruffin MT, et al. Pharmacokinetics (ff 6-gin- gerol, 8-gingerol, lO-gingeml, and 6-shogaol and conjugate metabo- lites in healthy human subjects [ J ]. Cancer Epidemiol Biomarkers Prey, 2008,17(8) :1930-1936.
  • 4Ahmed RS, Seth V, Banerjee BD. Influence of dietary ginger ( Zingi- ber officinales Rosc) on antioxidant defense system in rat: comparison with ascorbic acid [J]. Indian J Exp Biol, 2000,38(6) :604-606.
  • 5Bardutzky J, Meng X, Bouley J, et al. Effects of intravenous dime- thyl sulfoxide on ischemia evolution in a rat permanent occlusion model [ J]. J Cereb Blood Flow Metab, 2005,25(8) :968-977.
  • 6陆伟,蒋新国.脑内靶向给药研究进展[J].中国临床药学杂志,2002,11(6):384-387. 被引量:8
  • 7Sugawara T, Chan PH. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia [ J]. Antioxid Redox Signal,2003,5(5):597-607.

二级参考文献26

  • 1[1]Shanmuganathan K,Koudriakova T,Nampalli S,et al.Enhanced brain delivery of anti-HIV nucleoside 2-F-ara-ddI by xanthine oxidase mediated biotransformation[J].J Med Chem,1994,37(6):821.
  • 2[2]Yoshikawa T,Sakaeda T,Sugawara T,et al.A novel chemical delivery system for brain targeting[J].Adv Drug Del Rev,1999,36(2-3):255.
  • 3[3]Tsuji A,Tamai I.Carrier-mediated or specialized transport of drugs across the blood-brain barrier[J].Adv Drug Del Rev,1999;36(2-3):277.
  • 4[4]Kang YS,Pardridge WM.Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin[J].Pharm Res,1994,11(9):1257.
  • 5[5]Podulso JF,Curran GL,Gill JS.Putrescine-modified nerve growth factor:bioactivity,plasma pharmacokinetics,blood-brain/nerve barrier permeability,and nervous system biodistribution[J].J Neurochem,1998,71(4):1651.
  • 6[6]Wu D,Pardridge WM.CNS pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analouge coupled to a blood-brain barrier delivery system[J].J Pharmacol Exp Ther,1996,279(1):77.
  • 7[7]Pardridge WM,Wu D,Sakane T.Combined use of carboxyl-directed protein pegylation and vector-mediated blood -brain barrier durg delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration[J].Pharm Res,1998,15(4):576.
  • 8[8]Kang YS,Saito Y,Pardridge WM.Pharmacokinetics of [3H]-biotin bound to different avidin analogues[J].J Drug Target,1995,3(2):159.
  • 9[9]Shin SU,Wu D,Ramanathan R,et al.Functional and pharmacokinetic properties of antibody/avidin fusion proteins[J].J Immunol,1997,158(10):4797.
  • 10[10]Boado RJ,Tsukamoto H,Pardridge WM.Drug delivery of antisense molecules to the brain for treatment of Alzheimers disease and cerebral AIDS[J].J Pharm Sci,1998,87(11):1308.

共引文献10

同被引文献64

引证文献5

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部